Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Koa Accel CEO Francis Duhay tells Medtech Insight what his company looks for when choosing medtech ideas to support and how his experience as a physician and inventor informs his investment strategy.
Latest From Market Access
Some exciting changes to US Medicare payment rules will take effect in January for device-related procedures performed in different hospital settings. On this week’s podcast, executive editor Shawn M. Schmitt chats with senior reporter Sue Darcey, who covered these changes for Medtech Insight – as well news out of the Centers for Medicare and Medicaid Services (CMS) that it designated several new medical technologies for passthrough payments and will offer new home-use infusion therapy benefits.
The US Medicare agency is allowing more device procedures to be conducted at outpatient hospitals and ambulatory surgical centers (ASC), while approving several new devices for passthrough payments for three years under its Outpatient Prospective Payment System and ASC payment system final rule for 2020, released on 1 November.
With the current Brexit date less than a month away, the UK IVDs industry is busy providing support to UK manufacturers and the pathology sector in an attempt to ensure no one gets caught out. Coinciding with this are the ongoing preparations for the EU IVDR, and a raft of UK-specific issues for the diagnostics industry.
A new public consultation is looking at whether Australia’s rules prohibiting the supply of many types of self-testing IVDs are still fit for purpose.
The global market for fracture fixation products is expected to reach nearly $10.8bn by 2023, a CAGR of 5.9%. Internal fixation devices for small-bone fractures are expected to see the largest growth over the forecast period, according to a new analysis by Meddevicetracker.
Medicare administrative contractors for 19 US states have proposed supplying local Medicare coverage for hypoglossal nerve stimulation (HNS) provided by Inspire Medical Systems’ Inspire therapy to treat obstructive sleep apnea. See what company president and CEO Tim Herbert said about it here.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.